Last week we came together with global patient advocacy groups and key BMS leaders, including Natanya M. C., Narinder "Nani" Bhalla, Michelle Szabo and Scott Cooke to better understand global unmet needs in the cardiovascular space. We’re grateful to those who joined us and shared their perspective to drive collective progress in #cardiovascular care.
关于我们
百时美施贵宝是一家领先的生物制药企业,公司的使命是研发并提供创新和高质量的药物,帮助患者战胜严重疾病。我们专注于肿瘤、心血管、免疫学和纤维化等疾病领域帮助全球各地的无数患者。依托我们的研发组织,我们建立了一条潜在治疗方法的研发线,并且积极开展合作,借助外部创新拓展和加快推进我们的工作。 百时美施贵宝致力于满足中国未被满足的迫切的重大疾病需求,重点关注病毒性肝炎和免疫肿瘤两大疾病领域,引领行业发展,开展多元合作,加速提供创新的生物制药产品,以帮助中国患者战胜严重疾病。 为患者服务——这是我们一切行为的动力!
- 网站
-
http://www.bms.com
百时美施贵宝的外部链接
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Lawrence Township,NJ
- 类型
- 上市公司
- 领域
- biotechnology、innovation、great place to work、pharmaceuticals、research and development和healthcare
地点
百时美施贵宝员工
-
Bill Trebasky
Biopharmaceuticals Operations Executive
-
Mark Kaplan
Senior Director Translational Oncology
-
Lisa Filaferro, MBA, PHR
-
Lakshman Nagesh Yerramalla
PMO Executive Leader & Transformations Specialist ⇨ PMO Strategy & Optimization | Business Transformation Leadership | Strategic Portfolio Management…
动态
-
We are committed to advancing research across the HCM disease spectrum. Visit BMS Science to see upcoming and currently recruiting clinical trials. https://bit.ly/3MmaqYo
-
We’re re-entering the field of neuropsychiatry with renewed ambitions to make an impact on those affected by neurological conditions. Through our Live Your PosSCZible campaign, we’re partnering with inspiring voices to change the conversation around schizophrenia. Our commitment to providing more resources is just one aspect of our broader goal in changing how schizophrenia is seen, thought of, and talked about. When it comes to living with schizophrenia, we truly believe that, with the right support, anything is posSCZible. Learn more at https://bit.ly/TL-FB-RN
-
Hematologic diseases are diverse, and the nuances of each disease make treating them challenging. This #BloodCancerAwarenessMonth, Ridwaan Jhetam and Rosanna Ricafort discuss the range of modalities we’re exploring to deliver the next wave of advances in hematology and cell therapy. #DecodedByBMS #BMSAgainstBloodCancer
-
Visit exposehcm.com to learn more about hypertrophic cardiomyopathy (HCM) and our commitment to advancing research across the HCM disease spectrum. https://bit.ly/4e3Mmpb
-
We shared long-term safety and efficacy data from a Phase 3 study of our treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) at this year’s #ESCCongress. These results highlight our ongoing dedication to #cardiovascular innovation and our commitment to helping improve the lives of patients in the HCM patient community worldwide. Learn more: https://bit.ly/3z5yDPF #HypertrophicCardiomyopathy
-
The Coast 2 Coast 4 Cancer relay kicks off next week in the U.S.! Watch our colleagues train for the 225-mile segment and raise money for cancer research in honor of cancer patients! Learn more about #C2C4C: cancerbikeride.org
-
We look forward to sharing how we’re helping to advance cardiovascular research through our Phase 3 Librexia program at the #ESCCongress this weekend, along with our partner Johnson & Johnson Innovative Medicine.
-
Listen below to the a16z Bio + Health conversation with our Greg Meyers about how we're implementing artificial intelligence in nearly every facet of our business to advance our mission and what we look for in partners.
The real magic lies in developing AI to work seamlessly within complex workflows, ultimately leading to faster, more precise therapies. Recently, Greg Meyers, Executive Vice President and Chief Digital and Technology Officer at Bristol Myers Squibb, joined a16z general partner, Jorge Conde, to discuss how we can move from isolated experiments to truly integrated innovation. Listen on Raising Health: https://lnkd.in/g7tX6Xiq
-
Our scientists are focusing on new ways to advance research in thrombotic conditions, including exploring a new target called Factor XIa. See how our team is collaborating with Johnson & Johnson Innovative Medicine to explore ways to address the unmet need in stroke, ACS and AFib: https://bit.ly/3X09LRl